According to our knowledge and based on the literature published papers, the previous research has been more focused on outcomes in severe COVID-19 patients treated separately with an antiviral such as remdesivir or an anti–interleukin-6 receptor monoclonal antibody such as tocilizumab, and there is just one trial regarding remdesivir versus the combination of remdesivir plus tocilizumab in severe COVID-19 patients [41]. Here, IL6R is linked to COVID-19.